BMS ’ Opdivo/Yervoy combo cleared for kidney cancer

Approval was based on data from the Phase III CheckMate -214 clinical trial, in which the Opdivo (nivolumab) + Yervoy (ipilimumab) combination showed “a significant and unprecedented increase in overall survival (OS) in this patient population compared to a current standard of care, sunitinib,” according to BMS.07/16/2018
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news